[go: up one dir, main page]

AR110249A1 - Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo - Google Patents

Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo

Info

Publication number
AR110249A1
AR110249A1 ARP170103302A ARP170103302A AR110249A1 AR 110249 A1 AR110249 A1 AR 110249A1 AR P170103302 A ARP170103302 A AR P170103302A AR P170103302 A ARP170103302 A AR P170103302A AR 110249 A1 AR110249 A1 AR 110249A1
Authority
AR
Argentina
Prior art keywords
methyl
phenyl
free base
aminosulfonyl
piridinyl
Prior art date
Application number
ARP170103302A
Other languages
English (en)
Inventor
Yogeshwar Bachhav
Wilfried Schwab
Alexander Birkmann
Kurt Voegtli
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57421711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR110249(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Anti Infective Cures Gmbh filed Critical Aicuris Anti Infective Cures Gmbh
Publication of AR110249A1 publication Critical patent/AR110249A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere al campo de los agentes antivirales activos, particularmente la forma de hemihidrato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida así como a métodos para su fabricación. La presente también se refiere al uso del compuesto anterior en el tratamiento de infecciones por el virus herpes humano y en la preparación de composiciones farmacéuticas que comprenden dicho compuesto. Reivindicación 1: Un hemihidrato de la base libre de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida que tiene la fórmula molecular C₁₈H₁₈N₄O₃S₂ x 0,5 H₂O.
ARP170103302A 2016-11-28 2017-11-28 Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo AR110249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16200967 2016-11-28

Publications (1)

Publication Number Publication Date
AR110249A1 true AR110249A1 (es) 2019-03-13

Family

ID=57421711

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103302A AR110249A1 (es) 2016-11-28 2017-11-28 Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo

Country Status (22)

Country Link
US (3) US11021474B2 (es)
EP (3) EP4201934A1 (es)
JP (2) JP6978501B2 (es)
KR (2) KR102622289B1 (es)
CN (1) CN109996798B (es)
AR (1) AR110249A1 (es)
AU (3) AU2017365632B2 (es)
CA (1) CA3045059A1 (es)
CY (1) CY1124523T1 (es)
DK (2) DK3544976T3 (es)
ES (2) ES2941390T3 (es)
HR (1) HRP20210720T1 (es)
HU (1) HUE054703T2 (es)
LT (1) LT3544976T (es)
PL (1) PL3544976T3 (es)
PT (2) PT3544976T (es)
RS (1) RS61905B1 (es)
SI (2) SI3848369T1 (es)
SM (1) SMT202100279T1 (es)
TW (2) TWI811800B (es)
UY (1) UY37496A (es)
WO (1) WO2018096170A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
LT3544976T (lt) * 2016-11-28 2021-08-10 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
PL3544977T3 (pl) * 2016-11-28 2021-11-08 Aicuris Gmbh & Co. Kg Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki
MX2020003369A (es) 2017-10-05 2020-07-29 Innovative Molecules Gmbh Enantiomeros de tiazoles sustituidos como compuestos antivirales.
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CA3168721A1 (en) * 2020-03-26 2021-09-30 Jessica Redmer Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
EP3925595A1 (en) * 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
EP4581031A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
JP2025527942A (ja) 2022-08-29 2025-08-25 アセンブリー・バイオサイエンシーズ・インコーポレイテッド 新規な結晶形態

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496820A (en) * 1988-10-20 1996-03-05 Peraelampi; Markku Ophthalmic use of S-timolol hemihydrate
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
LT3544976T (lt) * 2016-11-28 2021-08-10 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
PL3544977T3 (pl) * 2016-11-28 2021-11-08 Aicuris Gmbh & Co. Kg Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki
CA3168721A1 (en) * 2020-03-26 2021-09-30 Jessica Redmer Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate

Also Published As

Publication number Publication date
PL3544976T3 (pl) 2021-11-02
EP4201934A1 (en) 2023-06-28
EP3544976B1 (en) 2021-02-17
KR102622289B1 (ko) 2024-01-05
UY37496A (es) 2018-06-29
HUE054703T2 (hu) 2021-09-28
JP2022024043A (ja) 2022-02-08
EP3848369B1 (en) 2023-01-11
WO2018096170A9 (en) 2019-12-19
PT3848369T (pt) 2023-04-10
SMT202100279T1 (it) 2021-07-12
EP3544976A1 (en) 2019-10-02
TWI811800B (zh) 2023-08-11
HRP20210720T1 (hr) 2021-09-03
AU2022263540A1 (en) 2022-12-08
KR102536156B1 (ko) 2023-05-25
AU2017365632B2 (en) 2021-07-15
JP2020509991A (ja) 2020-04-02
WO2018096170A1 (en) 2018-05-31
TWI737861B (zh) 2021-09-01
AU2021221901A1 (en) 2021-09-23
US11021474B2 (en) 2021-06-01
KR20190085115A (ko) 2019-07-17
RS61905B1 (sr) 2021-06-30
PT3544976T (pt) 2021-05-18
CN109996798A (zh) 2019-07-09
AU2017365632A1 (en) 2019-06-13
DK3544976T3 (da) 2021-05-10
DK3848369T3 (da) 2023-03-27
AU2021221901B2 (en) 2022-08-11
CN116804007A (zh) 2023-09-26
CA3045059A1 (en) 2018-05-31
JP6978501B2 (ja) 2021-12-08
US12152022B2 (en) 2024-11-26
EP3848369A1 (en) 2021-07-14
ES2870614T3 (es) 2021-10-27
SI3848369T1 (sl) 2023-07-31
KR20230075524A (ko) 2023-05-31
TW201825483A (zh) 2018-07-16
US20200123145A1 (en) 2020-04-23
CN109996798B (zh) 2023-05-05
SI3544976T1 (sl) 2021-08-31
LT3544976T (lt) 2021-08-10
CY1124523T1 (el) 2022-07-22
US20250042893A1 (en) 2025-02-06
ES2941390T3 (es) 2023-05-22
TW202207924A (zh) 2022-03-01
JP7289891B2 (ja) 2023-06-12
US20210269429A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
AR110249A1 (es) Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
AR118371A2 (es) Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CL2017000287A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas.
JOP20150301B1 (ar) بنزاميدات مستبدلة مع 3،1-ثيازول-2- يل
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
MX389697B (es) Nuevos derivados de pirazolopirimidina.
UY37997A (es) Agentes antivirales contra la hepatitis b
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
DOP2014000133A (es) Triazolopiridinas sustituidas
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
UY35293A (es) Isotiazoles sustituidos con amino
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
PE20181522A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
UY37498A (es) Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-20 metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma
AR110250A1 (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
MX2018014232A (es) Formulacion farmaceutica.
MX381234B (es) Agente preventivo y/o terapéutico de enfermedad inmune.
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv

Legal Events

Date Code Title Description
FC Refusal